Protocol Ledger

NCT05269355 · Phase II/III · TERMINATED

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Interventional Phase II/III clinical trial protocol NCT05269355 sponsored by PTC Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-23 Enrollment: 359 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05269355
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)359 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05269355
Protocol FieldVerified Registry Value
NCT IdentifierNCT05269355
Consolidated Lead SponsorPTC Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment359 participants (ACTUAL)
Registered Start Date2022-05-23
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI